Enfortumab vedotin (EV) is an antibody–drug conjugate with humanized antiNectin-4 antibody linked with a microtubule-disrupting agent called monomethyl auristatin E. Nectin-4 is a cellular adhesion protein that is overexpressed in urothelial cancer. EV was approved in December 2019 for patients with locally advanced or metastatic urothelial cancer who previously received platinum-based chemotherapy and immune checkpoint inhibitors. Here, we reviewed the clinical efficacy and safety data that led to the accelerated approval of EV for treating patients with metastatic urothelial cancer. Emerging clinical data on EV-based combinational therapeutic trials for metastatic urothelial cancer were also reviewed.
CITATION STYLE
Jain, R. K., Skelton, W. P., & Zhang, J. (2020). Emerging treatment options for the treatment of metastatic urothelial cancer: Therapeutic potential of enfortumab vedotin. Cancer Management and Research. Dove Medical Press Ltd. https://doi.org/10.2147/CMAR.S224223
Mendeley helps you to discover research relevant for your work.